MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tardive dyskinesia(TD)"

  • 2019 International Congress

    Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers

    C. Kutz (Colorado Springs, CO, USA)

    Objective: To elicit and compare the treatment goals of patients with tardive dyskinesia (TD), their care partners, and healthcare providers (HCP). Background: Tardive dyskinesia (TD)…
  • 2019 International Congress

    Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia

    S. Marder, C. Comella, C. Singer, C. Chepke, J. Burke, K. Farahmand, S. Siegert (Los Angeles, CA, USA)

    Objective: To examine long-term outcomes in adults with tardive dyskinesia (TD) who received once-daily valbenazine (VBZ) 40 mg or had a dose reduction from 80…
  • 2019 International Congress

    Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome

    S. Raju, K. Vyas (Bangalore, India)

    Objective: To report a case of clonazepam induced withdrawal emergent dyskinesia. Background: Withdrawal emergent syndrome was first described in 1973 when it was noticed that…
  • 2018 International Congress

    Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model

    P. Blanchet, G. Hernandez, S. Mahmoudi, M. Cyr, J. Diaz, D. Levesque (Montreal, QC, Canada)

    Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…
  • 2018 International Congress

    Tardive Myoclonus: A Case Report

    S. Gazioglu, F. Civil Arslan, V. Altunayoglu Cakmak, M. Korucuk, M. Ozmenoglu (Trabzon, Turkey)

    Objective: To report a patient with late-onset myoclonus after treatment with antipsychotic drugs which is a rare variant of tardive movement disorders. Background: The use…
  • 2018 International Congress

    Effects of Long-Term Valbenazine on Tardive Dyskinesia by Body Region: Shift Analyses of KINECT 4 Study Results

    C. Comella, C. Singer, S. Marder, J. Burke, K. Farahmand, R. Jimenez, S. Siegert (Chicago, IL, USA)

    Objective: To assess clinically meaningful improvements in tardive dyskinesia (TD) by evaluating changes in abnormal movements by body region after long-term valbenazine (VBZ) treatment. Background:…
  • 2018 International Congress

    Kratom withdrawal induced orobuccal dyskinesia

    K. Methawasin (Nakhon Nayok, Thailand)

    Objective: To describe the new observation of Kratom withdrawal that presented with the choreiform movement of lips and tongue. Background: Orobuccal dyskinesia is the hyperkinetic…
  • 2018 International Congress

    A case of tardive dyskinesia and parkinsonism following use of phentermine for weight loss

    R. Barmore, C. Hess, N. McFarland, M. Okun (Gainesville, FL, USA)

    Objective: To describe a case of tardive dyskinesia and parkinsonism following use of phentermine and briefly review the literature on tardive syndromes following use of…
  • 2018 International Congress

    Global Improvement and Patient Satisfaction: Results from a Long-Term, Open-Label, Rollover Study of Valbenazine in Tardive Dyskinesia

    S. Lessig, S. Marder, C. Verghese, J. Burke, R. Jimenez, S. Siegert, G. Liang (San Diego, CA, USA)

    Objective: To assess global improvement and patient satisfaction in participants with tardive dyskinesia (TD) who received long-term treatment with once-daily valbenazine (VBZ). Background: VBZ, approved…
  • 2018 International Congress

    Hospital Utilization Rates Following Antipsychotic Dose Reductions Among Patients With Bipolar and Major Depressive Disorders

    B. Carroll, F. Mu, R. Ayyagari, S. Ghandi (Frazer, PA, USA)

    Objective: To analyze the healthcare burden and incidence of Tardive dyskinesia (TD) due to antipsychotic dose reduction in patients with bipolar disorder (BD) and major…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley